By a News Reporter-Staff News Editor at Women's Health Weekly -- Current study results on Oncology have been published. According to news reporting out of Columbus, Ohio, by NewsRx editors, research stated, "Human serum albumin (HSA)-coated lipid nanoparticles (HSA-LNPs) loaded with phrGFP-targeted siRNA (HSA-LNPs-siRNA) were prepared and evaluated for gene downregulation effect in phrGFP-transfected breast cancer cells and the corresponding xenograft tumor model. HSA-LNPs-siRNA were successfully prepared with a particle size of 79.5±5.5 nm."
Our news journalists obtained a quote from the research from Ohio State University, "In phrGFP-transfected MCF-7 cells, HSA-LNPs-siRNA significantly decreased cell fluorescence even in the presence of fetal bovine serum (FBS). Moreover, cell fluorescence and phrGFP mRNA expression were significantly downregulated by HSA-LNPs-siRNA in phrGFP-transfected MCF-7, MDA-MB-231, and SK-BR-3 cells in comparison with control or HSA-LNPs-siRNA (scrambled). In phrGFP-transfected MCF-7 xenograft tumor model, tumor fluorescence was significantly decreased after three IV administrations of HSA-LNPs-siRNA at a dose of 3 mg/kg in comparison with siRNA alone. HSA-LNPs-siRNA demonstrated a superior pharmacokinetic profile in comparison with siRNA at a dose of 1mg/kg. These results show that the novel nonviral carrier, HSA-LNPs, may be used for the delivery of siRNA to breast cancer cells. Targeted delivery of siRNA to cancer cells may be a viable anti-cancer strategy with low toxicity."
According to the news editors, the research concluded: "In this study the novel nonviral carrier, human serum albumin-coated lipid nanoparticles (HSA-LNP) were demonstrated as an efficient delivery agent of siRNA to breast cancer cells."
For more information on this research see: Human serum albumin-coated lipid nanoparticles for delivery of siRNA to breast cancer. Nanomedicine, 2013;9(1):122-9. (Elsevier - www.elsevier.com; Nanomedicine - www.elsevier.com/wps/product/cws_home/703416)
Our news journalists report that additional information may be obtained by contacting L. Piao, Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH 43210, United States. Additional authors for this research include H. Li, L. Teng, B.C. Yung, Y. Sugimoto, R.W. Brueggemeier and R.J Lee (see also Oncology).
Keywords for this news article include: Ohio, siRNA, Therapy, Columbus, Genetics, Oncology, Nanoparticle, United States, Breast Cancer, Blood Proteins, Nanotechnology, Women's Health, Human Serum Albumin, Acute Phase Proteins, Emerging Technologies, Small Interference RNAs, North and Central America.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC